Humana - HUM Stock Forecast, Price & News

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Humana in the last twelve months. There are currently 2 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HUM shares.
View HUM analyst ratings or view top-rated stocks.

16 Wall Street research analysts have issued 12-month target prices for Humana's shares. Their HUM share price forecasts range from $506.00 to $652.00. On average, they expect the company's share price to reach $594.12 in the next twelve months. This suggests a possible upside of 18.2% from the stock's current price.
View analysts price targets for HUM or view top-rated stocks among Wall Street analysts.

Humana's stock was trading at $512.19 at the beginning of the year. Since then, HUM stock has decreased by 1.9% and is now trading at $502.43.
View the best growth stocks for 2023 here.

Humana saw a decrease in short interest during the month of February. As of February 28th, there was short interest totaling 2,020,000 shares, a decrease of 12.2% from the February 13th total of 2,300,000 shares. Based on an average daily trading volume, of 1,010,000 shares, the short-interest ratio is currently 2.0 days. Approximately 1.6% of the company's stock are sold short.
View Humana's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our HUM earnings forecast.

Humana will be holding an earnings conference call on Wednesday, April 26th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Humana Inc. (NYSE:HUM) announced its earnings results on Wednesday, February, 1st. The insurance provider reported $1.62 EPS for the quarter, beating analysts' consensus estimates of $1.46 by $0.16. The insurance provider had revenue of $22.44 billion for the quarter, compared to analyst estimates of $22.45 billion. Humana had a trailing twelve-month return on equity of 20.50% and a net margin of 3.02%. The company's revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.24 earnings per share.
Read the conference call transcript.

Humana announced a quarterly dividend on Thursday, February 16th. Stockholders of record on Friday, March 31st will be given a dividend of $0.885 per share on Friday, April 28th. This represents a $3.54 annualized dividend and a dividend yield of 0.70%. The ex-dividend date of this dividend is Thursday, March 30th. This is a positive change from the stock's previous quarterly dividend of $0.79.
Read our dividend analysis for HUM.

ETFs with the largest weight of Humana (NYSE:HUM) stock in their portfolio include iShares U.S. Healthcare Providers ETF (IHF), Janus Henderson US Sustainable Equity ETF (SSPX), Hennessy Stance ESG Large Cap ETF (STNC), WBI BullBear Quality 3000 ETF (WBIL), FIS Biblically Responsible Risk Managed ETF (PRAY), American Customer Satisfaction ETF (ACSI), Alpha Intelligent - Large Cap Value ETF (AILV) and Dividend Performers ETF (IPDP).

Humana (NYSE:HUM) pays an annual dividend of $3.15 per share and currently has a dividend yield of 0.63%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 14.29%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, HUM will have a dividend payout ratio of 9.91% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for HUM.

Humana updated its FY23 earnings guidance on Thursday, February, 23rd. The company provided earnings per share guidance of at least $28.00 for the period, compared to the consensus estimate of $28.04.

1,597 employees have rated Humana Chief Executive Officer Bruce D. Broussard on Glassdoor.com. Bruce D. Broussard has an approval rating of 87% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Humana investors own include UnitedHealth Group (UNH), NVIDIA (NVDA), Walt Disney (DIS), Visa (V), Mastercard (MA), Alibaba Group (BABA), Boeing (BA), Salesforce (CRM), Johnson & Johnson (JNJ) and JPMorgan Chase & Co. (JPM).

Humana trades on the New York Stock Exchange (NYSE) under the ticker symbol "HUM."

Humana's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (6.02%), Geode Capital Management LLC (1.75%), Morgan Stanley (1.33%), Newport Trust Co (1.07%), Norges Bank (1.06%) and Dimensional Fund Advisors LP (0.89%). Insiders that own company stock include Bruce D Broussard, Christopher H Hunter, David A Jr/Ky Jones, David A Jr/Ky Jones, Jorge S Mesquita, Joseph C Ventura, Samir Deshpande, Susan M Diamond, Timothy Alan Wheatley, Timothy S Huval and William Kevin Fleming.
View institutional ownership trends.

Shares of HUM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HUM stock can currently be purchased for approximately $502.43.

Humana (NYSE:HUM) has a market capitalization of $62.79 billion and generates $92.87 billion in revenue each year. The insurance provider earns $2.81 billion in net income (profit) each year or $22.04 on an earnings per share basis.

The company employs 67,100 workers across the globe.

Humana's mailing address is 500 West Main Street, LOUISVILLE KY, 40202. The official website for the company is www.humana.com. The insurance provider can be reached via phone at (502) 580-1000, via email at amysmith@humana.com, or via fax at 502-580-3639.